AptarGroup Inc Stock News

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read this week's edition.

AptarGroup (ATR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GPK vs. ATR: Which Stock Is the Better Value Option?

GPK vs. ATR: Which Stock Is the Better Value Option?

Style Box ETF report for SMMV

SON vs. ATR: Which Stock Is the Better Value Option?

SON vs. ATR: Which Stock Is the Better Value Option?

Sonoco (SON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AptarGroup found using ticker (ATR) have now 7 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 167 and 125 and has a mean target at 144.71. Given that the stocks previous close was at 112.26 this indicates there is a potential upside of 28.9%. The 50 day MA is 117.82 while the 200 day moving average is 127.32. The market capitalisation for the company is $7,363m. Visit the company website at: https://www.aptar.com [stock_market_widget type="chart" template="basic" color="green" assets=ATR" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $9,491m based on the market concensus. AptarGroup provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage.

SON vs. ATR: Which Stock Is the Better Value Option?

SON vs. ATR: Which Stock Is the Better Value Option?

AptarGroup (ATR) has priced an underwritten public offering of $400M aggregate principal amount of its 3.600% senior notes due 2032.Offering is expected to close on March 7,…

AptarGroup with ticker code (ATR) now have 7 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 167 and 125 and has a mean target at 144.71. With the stocks previous close at 116.87 this would imply there is a potential upside of 23.8%. The 50 day MA is 118.1 and the 200 day MA is 129.03. The market cap for the company is $7,931m. Find out more information at: https://www.aptar.com [stock_market_widget type="chart" template="basic" color="green" assets=ATR" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $9,820m based on the market concensus. AptarGroup provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions.